- Home
- AGEN vs FNWB Comparison
AGEN vs FNWB Comparison
Compare AGEN & FNWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- FNWB
- Stock Information
- Founded
- AGEN 1994
- FNWB 1923
- Country
- AGEN United States
- FNWB United States
- Employees
- AGEN N/A
- FNWB N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FNWB Banks
- Sector
- AGEN Health Care
- FNWB Finance
- Exchange
- AGEN Nasdaq
- FNWB Nasdaq
- Market Cap
- AGEN 96.2M
- FNWB 89.9M
- IPO Year
- AGEN 2000
- FNWB 2015
- Fundamental
- Price
- AGEN $3.83
- FNWB $10.93
- Analyst Decision
- AGEN Buy
- FNWB Hold
- Analyst Count
- AGEN 3
- FNWB 1
- Target Price
- AGEN $10.50
- FNWB $11.00
- AVG Volume (30 Days)
- AGEN 399.9K
- FNWB 15.9K
- Earning Date
- AGEN 03-13-2025
- FNWB 01-31-2025
- Dividend Yield
- AGEN N/A
- FNWB 2.54%
- EPS Growth
- AGEN N/A
- FNWB N/A
- EPS
- AGEN N/A
- FNWB N/A
- Revenue
- AGEN $160,427,000.00
- FNWB $50,768,000.00
- Revenue This Year
- AGEN N/A
- FNWB N/A
- Revenue Next Year
- AGEN $36.13
- FNWB $11.49
- P/E Ratio
- AGEN N/A
- FNWB N/A
- Revenue Growth
- AGEN 59.00
- FNWB N/A
- 52 Week Low
- AGEN $2.50
- FNWB $8.91
- 52 Week High
- AGEN $19.69
- FNWB $16.00
- Technical
- Relative Strength Index (RSI)
- AGEN 65.58
- FNWB 63.58
- Support Level
- AGEN $3.08
- FNWB $9.96
- Resistance Level
- AGEN $3.29
- FNWB $10.31
- Average True Range (ATR)
- AGEN 0.27
- FNWB 0.23
- MACD
- AGEN 0.08
- FNWB 0.11
- Stochastic Oscillator
- AGEN 94.84
- FNWB 85.09
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.